Blocking Arsenicals-induced Cutaneous Injury
阻止砷引起的皮肤损伤
基本信息
- 批准号:9750839
- 负责人:
- 金额:$ 73.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-08-15 至 2021-07-31
- 项目状态:已结题
- 来源:
- 关键词:AcidsAcuteAminesAnimal ModelAntidotesAntioxidantsAreaArsenicArsenicalsAttenuatedBiologicalBiological AssayBiological MarkersBiological ModelsBlood capillariesBritishBullaCarrier ProteinsCategoriesCell DegranulationChelating AgentsChemical AgentsChemical WarfareChemical Warfare AgentsChemicalsClinicalCutaneousCysteineDNA AlkylationDNA DamageDataDermalDermatologyDevelopmentDigestionDoseEdemaEffectivenessEicosanoidsEpidermisErythemaEventExposure toExtravasationFDA approvedFamily suidaeFelis catusFilamentGlutathioneGlycerolHairHealth protectionHepatic TissueHumanInfiltrationInflammationInflammatoryInflammatory ResponseInjuryInterceptKineticsLeadLesionLeukocytesLiquid substanceLungMediatingMiniature SwineModelingMolecularMolecular BiologyMolecular ChaperonesMolecular TargetMolecular WeightMusMustard AgentOrganOutcomeOxidative StressPainPathogenesisPathway interactionsPenetrationPeptide HydrolasesPopulationProcessProductionProtective AgentsProteinsReactionReactive Nitrogen SpeciesReactive Oxygen SpeciesRegulationRegulatory PathwayRenal TissueReportingResearchRuptureScientistSignal PathwaySignal TransductionSkinSkin injurySubcutaneous TissueTestingTherapeuticTight JunctionsTimeTissuesTopical applicationToxic effectToxicologyUnited States National Institutes of HealthVesicantsVesicleVisualWarWaterattenuationbasechemical threatchemokinecytokinediphenylexperienceexperimental studyin vitro Assayinhibitor/antagonistinterestkeratinocytelewisitemacrophagemast cellmouse modelnoveloccludinpre-clinicalpreventprogramsprotein transportpublic health relevanceresponsescreeningskin barrierskin lesionsmall moleculesystemic toxicitytranslational approachwater channel
项目摘要
DESCRIPTION (provided by applicant): Arsenicals, such as lewisite, diethylchloroarsine, diphenyl chlorarsine, and diphenyl cyanoarsine have been identified as potential war-threat agents, which could be used in chemical warfare. Topical exposure to these agents is known to result in severe cutaneous blistering and inflammation. In this application, we will test whether these arsenicals as listed above cause similar multiple cutaneous blistering and inflammatory effects in murine (haired but shaved) and mini-pig models as reported in humans. We will also investigate the molecular mechanisms by which these effects are manifested in these animal model systems. Our preliminary data indicate that in hairless murine model arsenicals by penetrating skin, rupture the cutaneous barrier functions as a consequence of disruption of proteins associated with tight junctions and water/glycerin transport. These effects are mediated mainly via activation of hippo signaling pathway protein, Yap besides others. Our data also show that the acute inflammation is mediated through the activation of unfolded protein response (UPR) signaling. UPR pathway is triggered by the arsenicals-dependent reactive oxygen species (ROS) production and activation of DNA damage response signaling. Based on these preliminary results, we will unravel whether crosstalk between these intricate signaling pathways results in the pathogenesis of painful blisters and inflammation. Based on these novel data, it is also tempting to investigate whether blocking these molecular targets by small molecules such as UPR signaling inhibitors also known as chemical chaperones, 4- phenylbutyric acid and salubrinal alone or in combination with arsenic chelator, British anti-lewisite (BAL) or antioxidant N-acetyl cysteine may intercept these effects. This will provide a molecular pathogenesis-based translational approach to develop effective interceptors/antidotes for blocking painful severe skin damage following cutaneous exposure to these chemicals. We are also proposing to test whether cutaneous exposure to these chemicals manifests systemic damage and whether topical application of these antidotes can prevent systemic effects of these chemicals. Three specific aims, each with their own milestones, are proposed to unravel the mechanism of pathogenesis by arsenicals in two animal models and to develop potential antidotes against these agents with defined window of their effectiveness. It is highly likely thatif found effective, the lead compounds based on their known toxicity profile and FDA approved use for other cutaneous blistering and inflammation-unrelated conditions can easily be approved. The outcome of the proposed research is likely to have a significant impact on human health protection in the unfortunate event of mass population exposure to this category of war-threat chemicals.
描述(由应用提供):砷,例如Lewisite,二乙基氯氨酸,二苯基氯氨酸和二苯基氰基氨基菌氨基已被确定为潜在的威胁性威胁性药物,可用于化学战。众所周知,对这些药物的局部暴露会导致严重的皮肤起泡和炎症。在此应用中,我们将测试上面列出的这些砷是否会导致鼠(头发但剃光)和人类报道的迷你猪模型在鼠(头发但剃光)中产生类似的皮肤发泡和炎症作用。我们还将研究这些作用在这些动物模型系统中表现出来的分子机制。我们的初步数据表明,在无毛鼠模型中,砷通过穿透皮肤而破裂,皮肤屏障的作用是由于破坏与紧密连接和水/甘油传输相关的蛋白质的破坏。这些作用主要是通过激活河马信号通路蛋白的激活来介导的。我们的数据还表明,急性炎症是通过激活展开的蛋白质反应(UPR)信号传导介导的。 UPR途径是由砷依赖性的活性氧(ROS)产生和DNA损伤响应信号传导激活触发的。基于这些初步结果,我们将解开这些复杂的信号通路之间的串扰是否导致疼痛的水泡和炎症的发病机理。基于这些新的数据,还很容易研究小分子(例如UPR信号传导抑制剂)也称为化学链酮,4-苯基丁基酸和单独的盐酸盐,还是与砷螯合剂,英国抗lewisite(BAL)或抗氧化物n-氧化物可能互动这些效果。这将提供一种基于分子发病机理的转化方法,以开发有效的拦截器/抗焦点,以阻止皮肤接触这些化学物质后疼痛的严重皮肤损伤。我们还建议测试皮肤暴露于这些化学物质是否表现出系统性损害,以及这些解毒剂的局部应用是否可以防止这些化学物质的全身作用。提出了三个具体目标,每个目标都有自己的里程碑,以揭示两个动物模型中砷的发病机理的机制,并以其有效性的定义窗口开发针对这些药物的潜在解毒剂。如果发现有效的话,很有可能会根据其已知的毒性概况和FDA批准的其他皮肤泡沫和炎症无关的条件使用的铅化合物很容易获得批准。拟议研究的结果可能会对人类健康保护产生重大影响,因为不幸的是大量人口暴露于这类威胁性的化学物质。
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Activating transcription factor 4 underlies the pathogenesis of arsenic trioxide-mediated impairment of macrophage innate immune functions.
激活转录因子 4 是三氧化二砷介导的巨噬细胞先天免疫功能受损的发病机制的基础。
- DOI:10.1016/j.taap.2016.07.015
- 发表时间:2016
- 期刊:
- 影响因子:3.8
- 作者:Srivastava,RiteshK;Li,Changzhao;Wang,Yong;Weng,Zhiping;Elmets,CraigA;Harrod,KevinS;Deshane,JessyS;Athar,Mohammad
- 通讯作者:Athar,Mohammad
Biological and environmental hazards associated with exposure to chemical warfare agents: arsenicals.
- DOI:10.1111/nyas.13214
- 发表时间:2016-08
- 期刊:
- 影响因子:5.2
- 作者:Li C;Srivastava RK;Athar M
- 通讯作者:Athar M
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mohammad Athar其他文献
Mohammad Athar的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mohammad Athar', 18)}}的其他基金
Optimization of Novel Molecular Target-based Drugs for Arsenical Skin Injury
砷皮肤损伤新型分子靶点药物的优化
- 批准号:
10259711 - 财政年份:2020
- 资助金额:
$ 73.35万 - 项目类别:
Optimization of Novel Molecular Target-based Drugs for Arsenical Skin Injury
砷皮肤损伤新型分子靶点药物的优化
- 批准号:
10023318 - 财政年份:2020
- 资助金额:
$ 73.35万 - 项目类别:
Optimization of Novel Molecular Target-based Drugs for Arsenical Skin Injury
砷皮肤损伤新型分子靶点药物的优化
- 批准号:
10700044 - 财政年份:2020
- 资助金额:
$ 73.35万 - 项目类别:
Optimization of Novel Molecular Target-based Drugs for Arsenical Skin Injury
砷皮肤损伤新型分子靶点药物的优化
- 批准号:
10886403 - 财政年份:2020
- 资助金额:
$ 73.35万 - 项目类别:
Core 4: Animal Breeding (UAB) and Exposure Core (MRIGLOBAL)
核心 4:动物育种 (UAB) 和暴露核心 (MRIGLOBAL)
- 批准号:
10249112 - 财政年份:2018
- 资助金额:
$ 73.35万 - 项目类别:
Project 1: Novel Pharmacological Inhibitors of Chemical Vesicants-mediated Cutaneous Injury
项目1:化学糜烂介导的皮肤损伤的新型药理抑制剂
- 批准号:
10249113 - 财政年份:2018
- 资助金额:
$ 73.35万 - 项目类别:
UAB Research Center of Excellence in Arsenicals
阿拉巴马大学砷化合物卓越研究中心
- 批准号:
9767149 - 财政年份:2018
- 资助金额:
$ 73.35万 - 项目类别:
UAB Research Center of Excellence in Arsenicals
阿拉巴马大学砷化合物卓越研究中心
- 批准号:
10249107 - 财政年份:2018
- 资助金额:
$ 73.35万 - 项目类别:
Core 3: Rexinoid Screening and Animal Core
核心 3:Rexinoid 筛选和动物核心
- 批准号:
10263928 - 财政年份:2017
- 资助金额:
$ 73.35万 - 项目类别:
相似国自然基金
多胺代谢通过eIF5A调控ARG1+巨噬细胞功能促进急性肾损伤慢性化转归的机制研究
- 批准号:82200773
- 批准年份:2022
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
多胺代谢通过eIF5A调控ARG1+巨噬细胞功能促进急性肾损伤慢性化转归的机制研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
西达本胺抑制HOXA9/FLT3信号轴协同Venetoclax靶向杀伤FLT3突变型急性髓系白血病及分子机制研究
- 批准号:82100195
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
干扰素α-1b、白细胞介素-2联合沙利度胺治疗急性髓系白血病的作用机制研究
- 批准号:82170151
- 批准年份:2021
- 资助金额:80 万元
- 项目类别:面上项目
氧化三甲胺在急性心肌梗死斑块破裂中作用机制的研究
- 批准号:81970308
- 批准年份:2019
- 资助金额:55 万元
- 项目类别:面上项目
相似海外基金
Lipid and metabolic mechanisms responsible for phosgene and phosphorus trichloride exposure toxicity
导致光气和三氯化磷暴露毒性的脂质和代谢机制
- 批准号:
10708475 - 财政年份:2023
- 资助金额:
$ 73.35万 - 项目类别:
Impact of Diet Induced Obesity on Acute Lung Injury
饮食引起的肥胖对急性肺损伤的影响
- 批准号:
10548843 - 财政年份:2022
- 资助金额:
$ 73.35万 - 项目类别:
Impact of Diet Induced Obesity on Acute Lung Injury
饮食引起的肥胖对急性肺损伤的影响
- 批准号:
10371363 - 财政年份:2022
- 资助金额:
$ 73.35万 - 项目类别:
Optimization and Characterization of Novel Antifungal Peptides
新型抗真菌肽的优化和表征
- 批准号:
10620239 - 财政年份:2022
- 资助金额:
$ 73.35万 - 项目类别:
Optimization and Characterization of Novel Antifungal Peptides
新型抗真菌肽的优化和表征
- 批准号:
10476773 - 财政年份:2022
- 资助金额:
$ 73.35万 - 项目类别: